Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Stage IVB, Recurrent or Persistent Carcinoma of the Cervix

Trial Name: A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus The Non-Platinum Doublet, Topotecan Plus Paclitaxel, with and without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix.

Protocol ID: GOG 0258

Eligibility:

 

Eligible Patients

  • Patients must have primary stage IVB, recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not amendable to curative treatment with surgery and/or radiation therapy.
  • Patients must meet required laboratory values.

Ineligible Patients

  • Patients previously treated with chemotherapy except when used concurrently with radiation therapy. 

            *Patients who have received concurrent paclitaxel and/or concurrent topotecan

             With radiation therapy are ineligible.

  • Patients with a concomitant malignancy other than non-melanoma skin cancer.
  • Patients with a prior invasive malignancy (except non-melanoma skin cancer) who have had any evidence of disease within the last 5 years or whose prior malignancy treatment contraindicates the current protocol therapy.
  • Patients with serious non-healing wound, ulcer, or bone fracture.
  • Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels.
  • Patients with history or evidence upon physical examination of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
  • Patients who are pregnant or nursing.  Patients of childbearing potential must agree to use contraceptive measures during study therapy, and for at least six months after completion of bevacizumab therapy.
  • Patients who have received therapy with any anti-VEGF drug, including bevacizumab.

Enrollment: • About 450 people will take part in this study at several medical centers.

Benefits:

 

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope one of the drug regimens being studied will be more useful against cancer compared to the usual treatment, there is no proof of this yet.  We do know that the information from this study will help doctors learn more about these drug regimens as a treatment for cancer.  This information could help future cancer patients.

Contact:

 

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Aug 17, 2011

Updated: Jan 18, 2013

« Return to Trials